论文部分内容阅读
目的探讨EGFR和HER2在胶质瘤复发中的意义。方法采用免疫组织化学方法(SABC法)观察24例复发胶质瘤患者原发肿瘤和复发肿瘤组织中EGFR和HER2的表达并与临床治疗指标进行相关分析。结果复发肿瘤组织较原发肿瘤组织中的EGFR表达减少(P=0.002),复发肿瘤组织较原发肿瘤组织中的HER2表达增加(P=0.006)。原发肿瘤中EGFR表达增高和患者无症状生存期呈显著正相关(Spearman等级相关系数r=0.441,P=0.031)。复发肿瘤中,EGFR表达增加和首次术后放疗呈正相关(Spearman等级相关系数r=0.446,P=0.029),HER2表达增加和首次术后化疗呈正相关(r=0.438,P=0.032)。结论 EGFR和HER2在胶质瘤复发前后的表达有统计学差异,且与术后治疗因素的选择有相关关系。
Objective To investigate the significance of EGFR and HER2 in the recurrence of glioma. Methods Immunohistochemistry (SABC method) was used to observe the expression of EGFR and HER2 in 24 patients with recurrent glioma and their correlations with clinical therapeutic parameters. Results The expression of EGFR in primary tumor was lower than that in primary tumor (P = 0.002). HER2 expression was higher in primary tumor than in secondary tumor (P = 0.006). There was a significant positive correlation between EGFR expression and asymptomatic survival rate in primary tumors (Spearman rank correlation coefficient r = 0.441, P = 0.031). In recurrent tumors, the increase of EGFR expression was positively correlated with the first postoperative radiotherapy (Spearman rank correlation coefficient r = 0.446, P = 0.029). The increased expression of HER2 was positively correlated with the first postoperative chemotherapy (r = 0.438, P = 0.032). Conclusion The expression of EGFR and HER2 in glioma recurrence before and after a statistically significant difference, and with the choice of postoperative therapeutic factors are related.